Multiple Myeloma Pipeline Clinical Trials, Growth, and Key Companies | Companies - Novartis, Incyte Corporation, Gracell Biotechnology

(Las Vegas Nevada United States), DelveInsight's, "Multiple Myeloma (MM) - Pipeline Insights, 2023," report provides comprehensive insights about 100+ companies and 130+ pipeline drugs in the Multiple Myeloma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download the sample @
https://www.delveinsight.com/sample-request/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Key Takeaways from the Multiple Myeloma Pipeline Pipeline Report
Over 100 + Companies and 130 + Pipeline Drugs for the Multiple Myeloma Pipeline are in various stages of development, and their anticipated acceptance in the Multiple Myeloma Pipeline market would significantly increase market revenue.

Leading Multiple Myeloma Pipeline companies developing novel drug candidates to improve the Multiple Myeloma Pipeline treatment landscape including Novartis, Incyte Corporation, Gracell Biotechnology, SpringWorksTherapeutics, Sana Biotechnology, Cytovia Therapeutics, Pfizer, and many others

Promising Multiple Myeloma Pipeline pipeline therapies in various stages of development include Elranatamab, Felzartamab, and many others.
Multiple Myeloma Pipeline Overview

Multiple myeloma is a clonal plasma cell proliferative disorder characterized by the abnormal increase of monoclonal paraprotein leading to evidence of specific end-organ damage. Unchecked, the excess production of these plasma cells can ultimately lead to specific end-organ damage. Most commonly, this is seen when at least one of the following clinical manifestations is present: hypercalcemia, renal dysfunction, anemia, or bone pain accompanied by lytic lesions. The exact etiology of multiple myeloma is unknown. However, frequent alterations and translocations in the promoter genes, especially chromosome 14, are commonly found in multiple myeloma and likely play a role in disease development. In addition, other oncogenes such as NRAS, KRAS, and BRAF may participate in plasma cell proliferation. Other factors contributing to disease occurrence include obesity, alcohol consumption, environmental causes such as insecticides, organic solvents, Agent Orange, and radiation exposure.

Multiple Myeloma Pipeline Pipeline Analysis: Drug Profile
Elranatamab: Pfizer
Felzartamab: Janssen Pharmaceutical
And many others

Discover more about the emerging Multiple Myeloma Pipeline Treatment Drugs @ https://www.delveinsight.com/sample-request/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Multiple Myeloma Pipeline Pipeline Therapeutics Assessment
Phases
DelveInsight's Report covers around 10+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued and inactive candidates

Route of Administration
Multiple Myeloma Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous

Molecule Type
Products have been categorized under various Molecule types such as
Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine

Product Type
Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.
Scope of the Multiple Myeloma Pipeline Pipeline Report
Coverage: Global
Key Multiple Myeloma Pipeline Companies: Pfizer, Janssen Pharmaceutical and many others
Key Multiple Myeloma Pipeline Pipeline Therapies Elranatamab, Felzartamab, and many others
Find out more about the @ Multiple Myeloma Pipeline Clinical Trials @ https://www.delveinsight.com/report-store/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Table of Contents
1. Multiple Myeloma Pipeline Introduction
2. Multiple Myeloma Pipeline Executive Summary
3. Multiple Myeloma Pipeline Overview
4. Multiple Myeloma Pipeline Pipeline Therapeutics
5. Multiple Myeloma Pipeline Late-Stage Products (Phase III)
6. Multiple Myeloma Pipeline Mid-Stage Products (Phase II)
7. Multiple Myeloma Pipeline Early Stage Products (Phase I/II)
8. Multiple Myeloma Pipeline Preclinical Stage Products
9. Multiple Myeloma Pipeline Discovery Stage Products
10. Multiple Myeloma Pipeline Therapeutic Assessment
11. Multiple Myeloma Pipeline Inactive Products
12. Multiple Myeloma Pipeline Collaborations Assessment- Licensing / Partnering / Funding
13. Multiple Myeloma Pipeline Unmet Needs
14. Multiple Myeloma Pipeline Market Drivers and Barriers
15. Appendix
16. About DelveInsight

Adya Kaul
info@delveinsight.com
+1(919)321-6187

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.

This release was published on openPR.